Centessa Pharmaceuticals Files 8-K with Corporate Updates
Ticker: CNTA · Form: 8-K · Filed: Sep 10, 2024 · CIK: 1847903
| Field | Detail |
|---|---|
| Company | Centessa Pharmaceuticals PLC (CNTA) |
| Form Type | 8-K |
| Filed Date | Sep 10, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, registration
Related Tickers: CNTA
TL;DR
Centessa Pharmaceuticals (CNTA) filed an 8-K confirming its Nasdaq listing and corporate details.
AI Summary
Centessa Pharmaceuticals plc announced on September 10, 2024, that it is filing a Form 8-K. The filing provides updated information regarding the company's corporate structure and registration details. It confirms the company's incorporation in England and Wales and lists its ordinary shares and American Depositary Shares (ADSs) trading under the symbol CNTA on the Nasdaq Stock Market, LLC.
Why It Matters
This filing provides routine corporate information and confirms the trading status of Centessa's shares on Nasdaq, which is important for investors monitoring the company's public filings.
Risk Assessment
Risk Level: low — This is a routine corporate filing with no new financial or operational information that would typically impact risk.
Key Players & Entities
- Centessa Pharmaceuticals plc (company) — Registrant
- September 10, 2024 (date) — Date of Report
- England and Wales (jurisdiction) — State of incorporation
- CNTA (ticker) — Trading Symbol
- Nasdaq Stock Market, LLC (company) — Exchange
FAQ
What is the primary purpose of this Form 8-K filing?
The primary purpose of this Form 8-K filing is to report current information regarding Centessa Pharmaceuticals plc's corporate structure and registration details.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on September 10, 2024.
In which jurisdiction is Centessa Pharmaceuticals plc incorporated?
Centessa Pharmaceuticals plc is incorporated in England and Wales.
What are the trading symbols and exchanges for Centessa Pharmaceuticals plc's securities?
Centessa Pharmaceuticals plc's ordinary shares and American Depositary Shares trade under the symbol CNTA on the Nasdaq Stock Market, LLC.
Does this filing indicate any changes in Centessa Pharmaceuticals' business operations or financial performance?
No, this filing is a routine corporate report and does not indicate any changes in business operations or financial performance.
Filing Stats: 957 words · 4 min read · ~3 pages · Grade level 10.8 · Accepted 2024-09-10 07:08:39
Filing Documents
- d857057d8k.htm (8-K) — 35KB
- d857057dex991.htm (EX-99.1) — 23KB
- d857057dex992.htm (EX-99.2) — 40KB
- g857057ex99_2p10g1.jpg (GRAPHIC) — 314KB
- g857057ex99_2p11g1.jpg (GRAPHIC) — 459KB
- g857057ex99_2p12g1.jpg (GRAPHIC) — 360KB
- g857057ex99_2p13g1.jpg (GRAPHIC) — 424KB
- g857057ex99_2p14g1.jpg (GRAPHIC) — 428KB
- g857057ex99_2p15g1.jpg (GRAPHIC) — 252KB
- g857057ex99_2p16g1.jpg (GRAPHIC) — 382KB
- g857057ex99_2p17g1.jpg (GRAPHIC) — 106KB
- g857057ex99_2p18g1.jpg (GRAPHIC) — 255KB
- g857057ex99_2p19g1.jpg (GRAPHIC) — 316KB
- g857057ex99_2p1g1.jpg (GRAPHIC) — 136KB
- g857057ex99_2p20g1.jpg (GRAPHIC) — 258KB
- g857057ex99_2p21g1.jpg (GRAPHIC) — 362KB
- g857057ex99_2p22g1.jpg (GRAPHIC) — 340KB
- g857057ex99_2p23g1.jpg (GRAPHIC) — 329KB
- g857057ex99_2p24g1.jpg (GRAPHIC) — 315KB
- g857057ex99_2p25g1.jpg (GRAPHIC) — 297KB
- g857057ex99_2p26g1.jpg (GRAPHIC) — 347KB
- g857057ex99_2p27g1.jpg (GRAPHIC) — 195KB
- g857057ex99_2p28g1.jpg (GRAPHIC) — 99KB
- g857057ex99_2p29g1.jpg (GRAPHIC) — 244KB
- g857057ex99_2p2g1.jpg (GRAPHIC) — 854KB
- g857057ex99_2p30g1.jpg (GRAPHIC) — 270KB
- g857057ex99_2p31g1.jpg (GRAPHIC) — 330KB
- g857057ex99_2p32g1.jpg (GRAPHIC) — 283KB
- g857057ex99_2p33g1.jpg (GRAPHIC) — 239KB
- g857057ex99_2p34g1.jpg (GRAPHIC) — 134KB
- g857057ex99_2p35g1.jpg (GRAPHIC) — 261KB
- g857057ex99_2p36g1.jpg (GRAPHIC) — 331KB
- g857057ex99_2p37g1.jpg (GRAPHIC) — 115KB
- g857057ex99_2p38g1.jpg (GRAPHIC) — 312KB
- g857057ex99_2p39g1.jpg (GRAPHIC) — 256KB
- g857057ex99_2p3g1.jpg (GRAPHIC) — 331KB
- g857057ex99_2p4g1.jpg (GRAPHIC) — 235KB
- g857057ex99_2p5g1.jpg (GRAPHIC) — 261KB
- g857057ex99_2p6g1.jpg (GRAPHIC) — 107KB
- g857057ex99_2p7g1.jpg (GRAPHIC) — 386KB
- g857057ex99_2p8g1.jpg (GRAPHIC) — 448KB
- g857057ex99_2p9g1.jpg (GRAPHIC) — 336KB
- 0001193125-24-216320.txt ( ) — 16417KB
- cnta-20240910.xsd (EX-101.SCH) — 3KB
- cnta-20240910_def.xml (EX-101.DEF) — 14KB
- cnta-20240910_lab.xml (EX-101.LAB) — 24KB
- cnta-20240910_pre.xml (EX-101.PRE) — 15KB
- d857057d8k_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. 99.1 Press Release, dated September 10, 2024 99.2 Corporate Presentation, dated September 2024 104 Cover Page Interactive Data (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 10, 2024 By: /s/ Saurabh Saha Name: Saurabh Saha, M.D., Ph.D. Title: Chief Executive Officer